Exp Clin Endocrinol Diabetes 2008; 116: S26-S29DOI: 10.1055/s-2008-1081484AbstractMucosal administration of autoantigen, if efficacious, is an attractive therapeutic approach for prevention of type 1 diabetes. It can prevent or delay autoimmune diabetes in animal models, but although shown to be safe has not yet been proven effective in human studies. Efficacy may depend upon the dose and route at which antigen is administered, the stage in type 1 diabetes pathogenesis at which treatment is initiated, and the study cohort that is treated. Here we address these issues and propose a clinical translation possibility for mucosal insulin administration in genetically at risk individuals.[...]© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New YorkGet connected:Table of contents | Abstract | Full text (Source: Experimental and Clinical Endocrinology and Diabetes)
MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.
Original source: http://www.thieme-connect.com/DOI/DOI10.1055/s-2008-1081484
